◎ Sugi Atlas

Atlas / Drug / Triamcinolone Acetonide

Triamcinolone Acetonide

drug
On this page

Also known as AdcortylAdcortyl in orabaseAllernazeAristocortAristocort aAristogelAudicortAureocortAzmacortExtracortFlutexFtorocortFX-006FX006Gppe ear dps capGppe ear ointKenacort-aKenalogKenalog in orabaseKenalog-10

Summary

Triamcinolone Acetonide (CHEMBL1504) is an approved small-molecule anti-inflammatory drug targeting NR3C1; indicated across 69 conditions including seasonal allergic rhinitis and frozen shoulder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • Targets: 1 (NR3C1)
  • Indications: 69 conditions
  • Clinical trials: 240
  • Chemistry: 434.5 Da · C24H31FO6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1504
NameTriamcinolone Acetonide
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID6436
ChEBICHEBI:71418
Molecular formulaC24H31FO6
Molecular weight434.5
InChIKeyYNDXUCZADRHECN-JNQJZLCISA-N

SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O

IUPAC name: (1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one

ChEBI definition: A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.

Pharmacological roles (ChEBI): anti-inflammatory drug, anti-allergic agent.

Also known as: Adcortyl, Adcortyl in orabase, Allernaze, Aristocort, Aristocort a, Aristogel, Audicort, Aureocort, Azmacort, Extracort, Flutex, Ftorocort

Patent coverage: 14,459 distinct patent families (51,670 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorAgonist8.20.9%P04150

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Nuclear receptor ROR-gamma, Prelamin-A/C, Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Nuclear receptor subfamily 1 group I member 2, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C18.7Ki2.01nMCHEMBL_ACT_7784257
NR3C18.51AC503.1nMCHEMBL_ACT_25175434
NR3C18.41AC503.9nMCHEMBL_ACT_25116108
NR3C18.36IC504.41nMCHEMBL_ACT_7784256
HIF1A8Potency10nMCHEMBL_ACT_4132752
HIF1A8Potency10nMCHEMBL_ACT_4519521
PGR7.7AC5020nMCHEMBL_ACT_25222675
LMNA5Potency10000nMCHEMBL_ACT_3645328

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
regulation of DNA-templated transcription1
regulation of transcription by RNA polymerase II1
apoptotic process1
chromosome segregation1
signal transduction1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
nuclear receptor-mediated steroid hormone signaling pathway1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

69 indications (21 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
seasonal allergic rhinitis4MONDO:0005324EFO:0003956
frozen shoulder4MONDO:0006763EFO:1000941
epicondylitis4MONDO:0001875EFO:1001896
gout4MONDO:0005393EFO:0004274
allergic rhinitis4MONDO:0011786EFO:0005854
bursitis4MONDO:0002471MONDO:0002471
injury4MONDO:0021178EFO:0000546
rheumatoid arthritis4MONDO:0008383EFO:0000685
skin disorder4MONDO:0005093EFO:0000701
pulmonary tuberculosis4MONDO:0006052EFO:1000049
type III hypersensitivity disease4MONDO:0007004EFO:1001222
tenosynovitis4MONDO:0004855EFO:1001435
fungal infectious disease4MONDO:0002041MONDO:0002041
anemia4MONDO:0002280MONDO:0002280
dermatitis4MONDO:0002406MONDO:0002406
asthma4MONDO:0004979MONDO:0004979
osteoarthritis4MONDO:0005178MONDO:0005178
multiple sclerosis4MONDO:0005301MONDO:0005301
diabetic retinopathy3MONDO:0005266EFO:0003770
osteoarthritis, knee3MONDO:0005416EFO:0004616
palmar fibromatosis3MONDO:0006345EFO:0004229
retinal vein occlusion3MONDO:0006951EFO:1001157
uveitis3MONDO:0020283EFO:1001231
anterior ischemic optic neuropathy3MONDO:0006649EFO:1000809
age-related macular degeneration3MONDO:0005150EFO:0001365
pemphigus vulgaris3MONDO:0008219EFO:0004719
chalazion3MONDO:0005844EFO:0007363
proliferative vitreoretinopathy3MONDO:0700115EFO:1001129
interstitial cystitis3MONDO:0018301EFO:0008507
lichen planus, oral3MONDO:0043923EFO:0008517
rhinitis3MONDO:0003014EFO:0008521
macular degeneration3MONDO:0003004EFO:0009606
osteoarthritis, hip3MONDO:0006629EFO:1000786
radiculopathy3MONDO:0002959MONDO:0002959
disease of the tendon3MONDO:0100010MONDO:0004857
otitis media with effusion3MONDO:0005892EFO:0007415
choroidal neovascularization3MONDO:0810000MONDO:0810000
alopecia areata2MONDO:0005340EFO:0004192
vitiligo2MONDO:0008661EFO:0004208
wet macular degeneration2MONDO:0005417EFO:0004683
hand dermatosis2MONDO:0006556EFO:1000706
atopic eczema2MONDO:0004980EFO:0000274
humerus fracture2MONDO:0005319EFO:0003943
keloid2MONDO:0005348EFO:0004212
mucous membrane pemphigoid2MONDO:0018746EFO:1000680
lichen planus2MONDO:0006572EFO:1000726
psoriasis2MONDO:0005083EFO:1001494
cataract2MONDO:0005129MONDO:0005129
breast neoplasm2MONDO:0021100MONDO:0007254
Vogt-Koyanagi-Harada disease2MONDO:0018092MONDO:0018092
ulnar neuropathy2MONDO:0007006EFO:1001224
glaucoma2MONDO:0005041MONDO:0005041
uveal melanoma2MONDO:0006486EFO:1000616
complex regional pain syndrome2MONDO:0019369EFO:1001998
hearing loss disorder1MONDO:0005365EFO:0004238
rotator cuff syndrome1MONDO:0007028EFO:1001250
mucositis1MONDO:0020579EFO:1001898
fibromatosis1MONDO:0005031EFO:0000497
acoustic neuroma1MONDO:0001569HP:0009588
optic papillitis0MONDO:0006879MONDO:0004037

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 240.

Phase distribution

PhaseTrials
Not specified59
PHASE449
PHASE249
PHASE347
PHASE2/PHASE313
PHASE1/PHASE210
PHASE110
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04207931PHASE4RECRUITINGTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
NCT05331664PHASE4RECRUITINGDropless Pars Plana Vitrectomy Study
NCT05806021PHASE4RECRUITINGThe Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis
NCT06578728PHASE4ACTIVE_NOT_RECRUITINGLocal Methotrexate Injections for the Treatment of Nail Psoriasis
NCT06897969PHASE4NOT_YET_RECRUITINGComparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment
NCT07006168PHASE4RECRUITINGEffects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation
NCT07014280PHASE4ACTIVE_NOT_RECRUITINGBevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
NCT07100145PHASE4NOT_YET_RECRUITINGEfficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus
NCT07453238PHASE4NOT_YET_RECRUITINGComparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata
NCT00779792PHASE4UNKNOWNEfficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation
NCT01230424PHASE4COMPLETEDEffect of Steroid Injections in a Knee With Osteoarthritis
NCT01652495PHASE4COMPLETEDEvaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection
NCT01720056PHASE4TERMINATEDVerapamil vs Steroid to Prevent Keloid Recurrence
NCT02120261PHASE4TERMINATEDUsing Saline for Myofascial Pain Syndromes (USAMPS)
NCT02379000PHASE4UNKNOWNTTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy
NCT02592629PHASE4TERMINATEDThe Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections
NCT02598869PHASE4WITHDRAWNPosterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
NCT02613455PHASE4UNKNOWNCorticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis
NCT02618603PHASE4UNKNOWNBotulinum Toxin A for Shoulder Pain After Stroke
NCT02806752PHASE4UNKNOWNIntravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
NCT02858297PHASE4COMPLETEDGlucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
NCT02877485PHASE4COMPLETEDThe Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation
NCT02917564PHASE4UNKNOWNTriamcinolone Injections for Persistent Choroidal Effusions Post Glaucoma Surgery
NCT02920177PHASE4TERMINATEDPlatelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement
NCT03120923PHASE4COMPLETEDCombined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome
NCT03166761PHASE4TERMINATEDParticulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
NCT03319784PHASE4WITHDRAWNAnalysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
NCT03382821PHASE4COMPLETEDComparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach
NCT03382925PHASE4TERMINATEDDoes Low-does Cervical Epidural Lidocaine Cause Transient Weakness?
NCT03535233PHASE4COMPLETEDTopical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata
NCT03636373PHASE4TERMINATEDPilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
NCT03895840PHASE4COMPLETEDThe Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA
NCT03991936PHASE4COMPLETEDBenefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
NCT03995641PHASE4WITHDRAWNThe Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation
NCT04002037PHASE4TERMINATEDDifferential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis
NCT04003376PHASE4UNKNOWNEfficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata
NCT04075136PHASE4WITHDRAWNOptical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
NCT04115644PHASE4TERMINATEDEffectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial
NCT04412148PHASE4UNKNOWNModified SALT Score for Alopecia Areata
NCT04701593PHASE4COMPLETEDUsing Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1
HALCINONIDEChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot